Woodline Partners LP Ventyx Biosciences, Inc. Transaction History

Woodline Partners LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.31 - $5.59 $875,894 - $2.12 Million	379,175 New	379,175 $875,000
Q3 2023 Nov 14, 2023	BUY	$29.8 - $40.3 $1.6 Million - $2.17 Million	53,783 Added 35.86%	203,783 $7.08 Million
Q2 2023 Aug 14, 2023	BUY	$28.53 - $39.55 $664,349 - $920,961	23,286 Added 18.38%	150,000 $4.92 Million
Q1 2023 May 15, 2023	BUY	$29.51 - $46.65 $197,746 - $312,601	6,701 Added 5.58%	126,714 $4.24 Million
Q4 2022 Feb 14, 2023	SELL	$24.16 - $36.38 $208,984 - $314,687	-8,650 Reduced 6.72%	120,013 $3.94 Million
Q3 2022 Nov 14, 2022	BUY	$12.64 - $38.7 $109,500 - $335,258	8,663 Added 7.22%	128,663 $4.49 Million
Q4 2021 Feb 14, 2022	BUY	$14.2 - $23.07 $1.7 Million - $2.77 Million	120,000 New	120,000 $2.38 Million

125

53M

35.3K

83K

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $105M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.